StockData
Labcorp Holdings Inc. logo

Labcorp Holdings Inc. (LH) KPIs and segments

LHNYSEServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 11/3016% above fair value
$368.24−4.22 (-1.13%)

Close on Nov 17, 2026Market cap $29.90BP/E 30.2Yield 0.78%

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Labcorp · năm tài chính kết thúc ngày 31 tháng 12

Nhìn nhanh KPI của Labcorp: 49 chỉ số vận hành, trong đó có Diagnostics Total Requisition Volume Growth, Diagnostics Total Price/Mix Change (YoY) và Diagnostics Total Revenue Growth (YoY), lấy từ 98 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Diagnostics($M)
2,9492,9012,7622,7292,7702,7492,6302,5862,5542,5252,4802,347
Biopharma Laboratory Services($M)
867836781793799785721767738707711
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)1
Diagnostics($M)
492523459419450483428360387442418354
Biopharma Laboratory Services($M)
15914212113613212310713112110799.9
Corporate Segment($M)
-154-130-117-100-111-139-132-189-173-180-129-174
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)1
Kỳ báo cáo trước đây (báo cáo lần cuối 2026)1
Diagnostics Total Requisition Volume Growth (YoY)(%)3
4.8%3.0%2.5%2.2%4.7%4.9%3.0%6.8%5.1%3.4%2.4%
Organic Requisition Volume Growth (YoY)(%)
3.1%1.8%1.1%1.1%3.5%3.4%0.9%4.0%2.2%1.2%0.3%
Acquisition Volume Contribution, Net of Divestitures (YoY)(%)
1.6%1.3%1.4%1.1%1.2%1.5%2.1%2.8%2.8%2.2%2.1%
Foreign Currency Impact on Requisition Volume (YoY)(%)
0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Diagnostics Total Price/Mix Change (YoY)(%)3
1.7%2.5%2.6%3.3%3.7%4.0%3.0%3.4%3.8%
Organic Price/Mix Change (YoY)(%)
1.3%1.8%1.8%3.0%2.8%1.1%0.7%1.1%2.7%
Acquisition Price/Mix Impact, Net of Divestitures (YoY)(%)
0.5%0.6%0.6%0.3%1.0%3.0%2.6%2.4%1.2%
Foreign Currency Impact on Price/Mix (YoY)(%)
-0.1%0.0%0.2%0.0%0.0%-0.1%-0.3%-0.1%-0.1%
Diagnostics Total Revenue Growth (YoY)(%)2
6.5%5.5%5.0%5.5%8.5%8.9%6.0%10.2%8.9%
Diagnostics Organic Revenue Growth (YoY)(%)
4.4%3.6%2.9%4.1%6.3%4.5%1.6%5.1%5.0%
Diagnostics Acquisition Revenue Contribution, Net of Divestitures (YoY)(%)
2.2%1.9%2.0%1.5%2.2%4.5%4.7%5.2%4.0%
BLS Ending Backlog($M)2
8,9208,7308,6408,7208,5808,7108,1807,9908,140
Next 12-Month Forecast Backlog Conversion($M)
2,8202,7502,6902,6602,6602,7102,5602,5302,590
BLS Ending Backlog Growth (YoY)(%)
3.9%0.2%5.6%9.2%5.4%10.0%3.5%-3.2%4.6%
BLS Trailing 12-Month Net Orders($M)
3,5903,3203,2903,3703,3403,3403,1502,9102,9002,8202,890
BLS Trailing 12-Month Book-to-Bill Ratio(×)1
1.101.031.041.091.091.111.071.001.001.04
BLS Quarterly Book-to-Bill Ratio(×)
1.131.140.941.160.891.18
BLS Total Revenue Growth (YoY)(%)4
8.5%6.5%8.2%3.4%8.3%11.0%1.5%10.4%2.6%
Central Laboratories Revenue Growth — Reported (YoY)(%)1
11.5%9.8%11.3%11.1%10.3%7.5%0.3%9.6%9.4%
Central Laboratories Revenue Growth — Organic Constant Currency (YoY)(%)
11.3%7.6%4.9%7.7%4.0%
Early Development Research Laboratories Revenue Growth — Reported (YoY)(%)1
0.4%-1.4%0.6%-13.5%3.3%20.4%4.4%12.3%
Early Development Revenue Growth — Organic Constant Currency (YoY)(%)
5.0%2.7%0.7%-15.1%1.1%18.0%
BLS Organic Revenue Growth (YoY)(%)
9.6%6.2%3.7%0.6%5.3%7.8%2.6%8.9%2.0%
BLS Foreign Currency Translation Impact (YoY)(%)
-0.3%1.8%5.5%2.8%3.0%3.2%-1.1%1.5%0.6%
Diagnostics Share of Consolidated Revenue(%)4
78.0%78.0%78.0%78.0%78.0%78.0%
Third-Party Payers / Managed Care (% of Consolidated Revenue)(%)
37.0%37.0%37.0%36.0%36.0%36.0%
Clients — Physicians, Hospitals & Health Systems (% of Consolidated Revenue)(%)
23.0%23.0%23.0%24.0%24.0%24.0%
Patients — Self-Pay & Co-Insurance (% of Consolidated Revenue)(%)
10.0%10.0%10.0%10.0%10.0%10.0%
Medicare & Medicaid (% of Consolidated Revenue)(%)
8.0%8.0%8.0%8.0%8.0%8.0%
Biopharma Laboratory Services Share of Consolidated Revenue(%)3
22.0%22.0%22.0%22.0%22.0%22.0%
Biopharma Clients — North America (% of Consolidated Revenue)(%)
9.0%8.0%8.0%9.0%9.0%9.0%
Biopharma Clients — Europe (% of Consolidated Revenue)(%)
9.0%10.0%10.0%9.0%9.0%9.0%
Biopharma Clients — Rest of World (% of Consolidated Revenue)(%)
4.0%4.0%4.0%4.0%4.0%4.0%
United States Consolidated Revenue($M)1
3,1693,0962,9142,9692,9322,8142,7382,6992,655
United States Share of Consolidated Revenue(%)
83.2%83.0%82.4%83.3%83.1%84.1%83.4%83.8%83.6%
Diagnostics Laboratories Segment Revenue($M)5
2,9492,9012,7622,7292,7702,7492,6302,5862,5542,5252,480
Diagnostics — Labor Expense($M)
1,2861,2231,1881,2081,2011,1551,1241,1641,1461,0731,056
Diagnostics — Laboratory Reagents & Supplies Expense($M)
636625614590589591587567538544560
Diagnostics — Segment Depreciation Expense($M)
70.868.163.865.366.465.461.769.165.163.161.7
Diagnostics — Other Segment Operating Expenses($M)
466462438446463454430427417403384
Diagnostics — Segment Adjusted Operating Income($M)1
492523459419450483428360387442418
Diagnostics — Adjusted Operating Margin(%)
16.7%18.0%16.6%15.4%16.3%17.6%16.3%13.9%15.2%
Biopharma Laboratory Services Segment Revenue($M)6
867836781793799785721767738707711
BLS — Labor Expense($M)
320313309316314302290296293286290
BLS — Laboratory Supplies & Kit Expense($M)
126131122117120131111122110107104
BLS — Clinical Trial Specimen & Kit Shipping Expense($M)
13012211110410298.2959493.789.788.4
BLS — Segment Depreciation Expense($M)
28.427.728.629.4292928.629.631.530.331.2
BLS — Other Segment Operating Expenses($M)
10310189.790.81031019094.48987.297.5
BLS — Segment Adjusted Operating Income($M)1
15914212113613212310713112110799.9
BLS — Adjusted Operating Margin(%)
18.3%17.0%15.5%17.2%16.5%15.7%14.8%17.0%16.4%
General Corporate & Unallocated Expenses($M)1
154130117100111139132189173180129
Intercompany Segment Revenue Eliminations($M)
-5.60-5.80-5.10-5.70-5.20-6.30-5.80-23.8-9.20-11-14
Unbilled Services (Contract Assets), Gross($M)4
149166166164163162159161168159128193
Unbilled Services, Net — Current($M)
146162157156162151153166158120185
Revenue Recognized from Beginning Unearned Revenue Balance($M)
1934.158.31634.468.920.226.851
Diagnostics Trade Accounts Receivable, Net($M)
1,6251,5471,5131,349
BLS Trade Accounts Receivable, Gross($M)1
825833808791
BLS Allowance for Credit Losses($M)
37.137.23336.4
Unconditional Purchase Commitments — Laboratory Reagents & Equipment($M)3
112115122129
Unconditional Purchase Commitments — Due Within 1 Year($M)
4.8020.927.834.7
Unconditional Purchase Commitments — Due in Year 2($M)
32.720.520.520.5
Unconditional Purchase Commitments — Due in Year 3($M)
74747474
Operating Lease Liabilities — Noncurrent($M)3
675661657683692713696676701643625649
Operating Lease Liabilities — Current($M)
183180183191187186183185184182171166
Finance Lease Liabilities — Noncurrent($M)
61.161.662.26364.365.666.574.375.276.977.178.6
Finance Lease Liabilities — Current($M)
5.204.704.604.604.504.304.806.106.306.706.406.40
Identifiable Intangible Assets, Gross($M)8
6,1976,0925,9775,8875,7715,6295,5115,4335,4445,1505,1495,058
Accumulated Amortization of Intangible Assets($M)
2,4802,4132,3412,2912,1992,1342,0241,9441,9031,8181,7551,716
Intangible Asset Amortization Expense($M)
78.778.175.672.669.568.369.670.463.762.260.1
Estimated Future Amortization Expense — Year 1($M)
81.215222329076.314220827271125183235
Estimated Future Amortization Expense — Year 2($M)
308297288277281268266261260237237226
Estimated Future Amortization Expense — Year 3($M)
300290280269268255254248251228228217
Estimated Future Amortization Expense — Year 4($M)
287277267256260247246241240217217206
Estimated Future Amortization Expense — Year 5($M)
279268259247247235232227232209209197
Estimated Future Amortization Expense — After Year 5($M)
1,9221,8531,7671,6971,8741,7781,7241,6831,9151,7361,7371,675
Remaining Share Repurchase Authorization($M)1
1,3793797328301,0551,0801,2801,2801,355430532530
Common Shares Repurchased — Quarterly / Annual
0.001.300.400.900.100.800.000.300.30
Incremental Dilutive Shares from Equity Awards
0.500.300.600.600.500.700.400.200.60
U.S. Medical & Diagnostic Laboratories Industry Revenue — Census QSS (NAICS 6215)($M)3
20,52819,56919,99719,67719,71818,72219,10418,89318,48317,96317,943
U.S. Ambulatory Health Care Services Revenue — Census QSS (NAICS 621)($M)
414,886395,174407,176398,164389,960373,423380,950366,854362,208347,178347,128
U.S. Outpatient Care Centers Revenue — Census QSS (NAICS 6214)($M)
45,10844,02245,30042,79741,83240,03040,60237,89737,22736,08737,030
U.S. Hospitals Industry Revenue — Census QSS (NAICS 622)($M)
47,89646,67446,83446,29545,37045,35845,28443,77843,50543,70943,264
U.S. Personal Consumption Expenditures — Health Care Services (SAAR)
3,858.703,790.303,699.903,667.003,614.903,529.803,464.703,417.803,358.203,288.203,244.403,159.40
ClinicalTrials.gov Registered Studies Referencing Labcorp / Covance / Monogram
7.002.002.003.004.003.006.005.001.002.0010.0010.00
Quest Diagnostics Inc. (DGX) — Revenue($M)1
3,0973,0432,8952,8062,8162,7612,6522,6212,4882,3972,3662,288
Quest Diagnostics Inc. (DGX) — Operating Income($M)
479459399386386438346361330355300267
Fortrea Holdings Inc. (FTRE) — Revenue($M)1
692678636660701710651697675662662710
Fortrea Holdings Inc. (FTRE) — Operating Income($M)
1515-3-14-9-330-520-56-18-51-37-24
Charles River Laboratories International (CRL) — Revenue($M)1
9831,0049969941,0051,0329841,0031,0101,0261,0121,013
Charles River Laboratories International (CRL) — Operating Income($M)
203120120-28313410075-168117152126133
IQVIA Holdings Inc. (IQV) — Revenue($M)1
4,4284,3684,1514,3644,1004,0173,8293,9583,8963,8143,7373,868
IQVIA Holdings Inc. (IQV) — Operating Income($M)
572506514627553506496626550520506501
Medpace Holdings, Inc. (MEDP) — Revenue($M)1
716707707708660603559537533528511498
Medpace Holdings, Inc. (MEDP) — Operating Income($M)
16614714215314212611412511210510487
Exact Sciences Corp. (EXAS) — Revenue($M)1
878851811707713709699638647
Exact Sciences Corp. (EXAS) — Operating Income($M)
-83-26-2-96-876-39-26-107-68
Natera, Inc. (NTRA) — Revenue($M)1
794753697665592547502476440413368311
Natera, Inc. (NTRA) — Operating Income($M)
-68-76-94-23-98-110-79-65-39-44-74-85
Guardant Health, Inc. (GH) — Revenue($M)1
361335302281265232203202191177168155
Guardant Health, Inc. (GH) — Operating Income($M)
-133-129-121-121-99-106-111-126-117-101-100-198
NeoGenomics, Inc. (NEO) — Revenue1
NeoGenomics, Inc. (NEO) — Operating Income($M)
-8-10-18-13-27-48-28-18-21-22-31-19
Consolidated Revenue($M)
3,8103,7313,5383,5163,5643,5273,3453,3293,2823,2213,1773,033
Cost of Revenues($M)
2,7022,6192,5242,5232,5382,4812,3972,4332,3782,2952,2792,212
Gross Profit($M)
1,1081,1121,0149931,0251,046948896904926897821
Selling, General and Administrative Expenses($M)
611577551538553579546595569558508533
Consolidated Operating Income($M)
402452381268397395326217254295321-123
Net Earnings Attributable to Labcorp Holdings Inc.($M)3
263299278165261238213143169205228-167
Diluted Earnings Per Share($)
3.223.643.353.122.842.5222.432.69
Weighted-Average Diluted Shares
81.6082.0082.9083.7083.9084.3084.4084.3084.70
Dividends Declared Per Common Share($)
0.720.720.720.720.720.720.720.720.720.72
Operating Cash Flow($M)5
56444619261438762118.5777277561-29.8580
Depreciation and Amortization($M)
183179173173171170167171162157155146
Stock-Based Compensation($M)
30.834.931.729.729.234.132.827.32730.831.627
Net Cash Paid for Acquisitions($M)
2562262022582611053.587.845833.9259155
Common Stock Repurchased($M)
-03549822525200-075.175-9
Common Stock Dividends Paid($M)
58.258.761.259.359.959.961.660.160.560.462.161.1
Total Assets($M)6
18,92518,53219,08718,39318,26218,06017,60418,37918,61316,71216,53116,725
Cash and Cash Equivalents($M)
2621429815325986473691,5191,51726599.3537
Accounts Receivable, Net($M)
2,4132,3422,2892,1042,1092,1212,1231,9442,0592,0892,0841,913
Inventories($M)
538562498535522508488493483442475475
Goodwill($M)
7,1777,0306,9556,7906,6826,5516,4216,3706,4826,2206,2196,143
Intangible Assets, Net($M)
3,7173,6783,6363,5963,5713,4943,4873,4893,5413,3323,3943,342
Total Shareholders' Equity($M)
8,8488,6078,7298,6208,6978,4738,3078,0528,1708,0067,9607,875

14 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Fiscal calendar: Labcorp Holdings Inc. operates on a calendar fiscal year ending December 31 (latest quarterly period: Q3 2026 ended September 30, 2026; latest annual period: FY2025 ended December 31, 2025).
  • Segment architecture: Following the June 30, 2023 spin-off of its late-stage clinical CRO business into Fortrea Holdings Inc. (NASDAQ: FTRE), Labcorp operates two reportable segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS, comprising Central Laboratories and Early Development Research Laboratories).
  • Derived cells are strictly limited to calendar period-splitting (`Q4 = full year (10-K) − nine months (10-Q)` for fourth-quarter segment expense lines and U.S. revenue, and `quarter = year-to-date − previous year-to-date` for cash-flow items).
  • Constant-currency growth rates for BLS Central Laboratories and Early Development are retained alongside reported growth because management explicitly issues full-year sub-segment guidance on an organic constant-currency basis and FX translation averaged >250 bps across recent quarters.

Không hiện vì thiếu các kỳ gần đây (11)

  • Annual Diagnostic Test Volume ('more than 700 million' / 'more than 750 million' tests per year in Form 10-K Item 1 & Investor Day) — disclosed strictly as an inequality bound rather than an exact point count.
  • Patient Service Centers Count ('more than 2,200' PSCs including 'more than 400' Walgreens locations) — disclosed strictly as an inequality bound across Form 10-K and Investor Day presentations.
  • In-Office Phlebotomists Count ('more than 6,800' phlebotomists located in client offices) — disclosed strictly as an inequality bound in Form 10-K Item 1.
  • Global Employee Headcount ('nearly 70,000' FTEs in FY2024; 'nearly 71,000' FTEs in FY2025) — disclosed strictly as an inequality/approximate bound in Form 10-K Item 1.
  • FDA Drug & Therapeutic Approvals Supported ('more than 75%' / 'more than 85%' of new FDA approvals) — disclosed strictly as an inequality bound.
  • Absolute Scope 1 & Scope 2 GHG Emissions (tCO2e) and Total Waste Generated (metric tons) — available only through FY2024 from 2020–2024 Corporate Responsibility Reports because the 2025 Corporate Responsibility Report PDF on labcorp.com is behind HTTP 403 WAF protection (lacks FY2025 continuity).
  • Monthly Average Price Paid Per Repurchased Share — discontinuous in months with zero share repurchases (including July–September 2026).
  • Standalone Parent vs. Subsidiary Subtraction — Labcorp Holdings Inc. reports consolidated US GAAP statements and has no standalone parent operating statements; clinical CRO operations spun off into Fortrea Holdings Inc. (FTRE) in June 2023 are already segregated in discontinued operations.
  • Diagnostics Laboratories — Volume, Price/Mix & Network › Diagnostics Total Revenue Growth (YoY) › Diagnostics Foreign Currency Translation Impact (YoY) (insufficient consecutive latest periods)
  • U.S. Clinical Lab Macro Indicators, ClinicalTrials.gov & Peer Benchmarks › NeoGenomics, Inc. (NEO) — Revenue (insufficient consecutive latest periods)
  • Consolidated Financial & Historical Segment Context (GAAP) › Consolidated Operating Income › Restructuring and Special Charges (insufficient consecutive latest periods)

Dữ liệu cập nhật 2026-11-06.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Labcorp

See a number that looks wrong?